Clinical Trials Directory

Trials / Unknown

UnknownNCT02749734

Clinical Study of Subretinal Transplantation of Human Embryo Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Macular Degeneration Diseases

Status
Unknown
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
15 (estimated)
Sponsor
Southwest Hospital, China · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study was to determine the safety and therapeutic effect of sub-retinal transplantation of human embryo stem cell derived retinal pigment epitheliums (hESC-RPE) in patients with macular degeneration diseases, and explore new treatment modalities for macular degeneration diseases (Age-related macular degeneration and Stargardt's macular dystrophy).

Conditions

Interventions

TypeNameDescription
PROCEDURESubretinal transplantationTransplant hESC-RPE into subretinal space of patients with macular degeneration

Timeline

Start date
2015-05-01
Primary completion
2018-12-01
Completion
2019-12-01
First posted
2016-04-25
Last updated
2018-01-31

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT02749734. Inclusion in this directory is not an endorsement.

Clinical Study of Subretinal Transplantation of Human Embryo Stem Cell Derived Retinal Pigment Epitheliums in Treatment (NCT02749734) · Clinical Trials Directory